The present invention relates to an improved process for preparation of mirtazapine, wherein 1-(3-hydroxymethylpyridyl-2)-2-phenyl-4-methylpiperazine is subjected to cyclization in the presence of a solvent to get mirtazapine.

The present invention relates to an improved process for large scale production of octreotide acetate. The invention also relates to pharmaceutical composition of octreotide acetate.

The present invention relates to novel polymorphs of 4-hydroxy Atomoxetine hydrochloride and process for the preparation thereof. The present invention also relates to crystalline monohydrate and anhydrate forms of 4- hydroxy Atomoxetine hydrochloride.

The present invention relates to oral solid dosage forms comprising a combination of ezetimibe and HMG-CoA reductase inhibitor, in the form of inlay-tablet or compression-coated tablet. The invention also relates to process of preparing said dosage forms.

An oral pharmaceutical composition comprising clopidogrel or its salts thereof, in admixture with at least one pharmaceutically acceptable excipient, wherein said composition exhibits at least 35 mg drug release within 45 minutes when measured in pH 4.5 acetate buffer and is bioequivalent to the commercially availab...

The present invention relates to an improved process for the preparation of Bosentan or its salt. The present invention also relates to an improved process for the deprotection of hydroxy protected Bosentan. The present invention further relates to a pharmaceutical composition comprising Bosentan of formula I with e...

The present invention relates to a process for the preparation of 3-(2'-substituted biphenyl-4-ylmethyl)-2-ethoxy-3H-benzimidazole-4-carboxylic acid derivatives, the intermediate compounds of Candesartan cilexetil, by condensing 2-Ethoxy-3H-benzimidazole-4-carboxylic acid derivative with 2-substituted 4'-halomethyl-...

PROCESS FOR PREPARING NITROFURANTOIN MONOHYDRATE Disclosed herein is an improved process for preparing nitrofurantoin monohydrate. The process comprising suspending nitrofurantoin in polar organic solvents, adding water to resultant mixture, heating the resultant mixture and isolating nitofurantoin monohydrate. ...

A composition comprising tadalafil or its pharmaceutically acceptable salts thereof together with one or more pharmaceutically acceptable excipients, wherein said composition is prepared using a solution/ dispersion of tadalafil in a suitable solvent, wherein said solution/ dispersion of tadalafil is free of any oth...

The invention provides aqueous concentrated formulation of linezolid. More particularly, the invention provides aqueous concentrated formulation of linezolid comprising atleast one solubilizer wherein the formulation is preferably administered intravenously.

NOVEL CRYSTALLINE FORMS OF 4-[4-[4-(HYDROXYDIPHENYLMETHYL)-l- PIPERIDINYL]-l-HYDROXYBUTYL]-A,A-DIMETHYLBENZENEACETIC ACID HYDROCHLORIDE AND PROCESS OF PRODUCING THE SAME Abstract of the Invention Disclosed herein are novel crystalline forms of 4-[4-[4-(Hydroxydiphenylmethyl)-l-piperidinyl]-1 -hydroxybutyl]-a, a-...

The invention relates to hemifumarate salt of Tenofovir disoproxil and processes for preparing tenofovir disoproxil hemifumarate.

The present invention provides an enzymatic process for the preparation of (S)-5-(4-Fiuoro-phenyl)-5-hyciroxy-1morphoiin-4-yl-pentan-1-one by the reduction of 1-(4-Fluoro-phenyi)-5-morpholin-4-yl-pentane-1,5-dione by using a suitable enzyme or by the resolution of (R, S)-5-(4-Fluoro-phenyl)-5-hydroxy-1morpholin-4-yl...

This invention relates to stabilized lanthanum carbonate composition wherein lanthanum compound is in low hydration state. More particularly, the present invention is directed to a chewable pharmaceutical composition comprising lanthanum carbonate having less than three molecules of water, preferably in anhydrous fo...

The present invention relates to eight novel impurities of Piperaquine and process for the preparation thereof.

The invention relates to stable pharmaceutical compositions comprising dexlansoprazole or its pharmaceutically acceptable salts and an inert capsule shell, wherein said inert capsule shell is alternatively over coated with multiple layers of said dexlansoprazole or its pharmaceutically acceptable salts and an enteri...

The present invention relates to an improved process for the preparation of Oseltamivir phosphate using acetamido azide and N- acetyl aziridine.

The present invention relates to pharmaceutical compositions comprising novel combinations of efavirenz, tenofovir, emtricitabine with HIV integrase inhibitors which exhibits antiretroviral activity.

The present invention is to provide an improved process for the preparation of Imatinib or pharmaceutically acceptable salt. The present invention is also to provide a process for the preparation of Imatinib mesylate polymorphic form α.

The invention relates to pharmaceutical compositions comprising frovatriptan or its pharmaceuticalally acceptable salts thereof and atleast one pharmaceutically acceptable excipient and a process for preparing the same.

The present relates to an improved process for the preparation of Iloperidone or its pharmaceutically acceptable salt by reacting l-[4-(3-chloropropoxy)-3-methoxyphenyl] ethanone of formula III with 6-fluoro-3-(4-piperidinyl)-l,2-benzisoxazole of formula II or its salt in presence of organic base in a solvent. ...

The present invention is to provide an improved process for the preparation of Sunitinib, solvates or its pharmaceutically acceptable salts having substantially free of N, N-dimethyl amide analog represented by compound of formula-2, N, N-diethyl amide analog represented by compound of formula-3, N-ethyl amide analo...

The present invention relates to a process for preparing pure Prasugrel free base by purification and its further conversion into pharmaceutically acceptable salts of Prasugrel. The present  invention  also  provides  crystalline  form  of Prasugrel  free  base.

The present invention provides an improved process for the preparation of Adefovir Dipivoxil and its pharmaceutically acceptable salts or solvates.

The present invention relates to an improved process for the preparation of Tolvaptan. The present invention further relates to a process for the preparation of Tolvaptan by using Keto protected intermediate.

The present invention is to provide an improved process for the preparation of Olopatadine or it salt. The present invention also provides a process for increasing the (Z) / (E) ratio of Olopatadine or its salt thereof.

The present invention provides an improved process for the preparation of compound of Formula-II, which is used an intermediate in the preparation of HMG-CoA reductase inhibitors of general Formula-I

The present invention provides an improved process for the preparation of quinoline-3-carboxylate compounds which are useful intermediates in the preparation of HMG-CoA reductase inhibitors like Pitavastatin.

The present invention relates to an improved process for the preparation of Dronedarone or its pharmaceutically acceptable salt.

An improved process for the preparation of Levofloxacin" The present invention relates to an improved process for the preparation of Levofloxacin by reacting (S)-(-)9,10-difluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido [1,2,3-de][1,4] benzoxazine-6-carboxylic acid with N-methyl piperazine, wherein the improvement comp...

The present invention relates to a novel polymorphic forms of (3S,8S,9S,12S)-3,12-Bis(1,1- dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-[[4-(2-pyridinyl)phenyl] methyl]- 2,5,6,10,13-pentaazatetradecanedioic acid dimethyl ester (Atazanavir freebase) and process for the preparation thereof. ...

The present invention relates to Amorphous form of (3S)-tetrahydrofuran-3-yl (1S,2R)-3- [[(4-aminophenyl)sulfonyl](isobutyl)amino]-l-benzyl-2-(phosphonooxy) propyl- carbamate monocalcium salt and process for the preparation thereof. In particular the present invention relates to a stable amorphous form of (3S)-tetra...

The present invention relates to an improved process for the preparation of Milnacipran hydrochloride wherein, 2-hydroxymethyl-1-phenyl-cyclopropanecarboxylic acid diethylamide is reacted with chlorinating agent to give chloro derivative characterized in that after completion of the reaction, reaction mass is treate...

The present invention provides an improved process for the preparation of Sevelamer or it"s pharmaceutically acceptable salts thereof, wherein polyallylamine hydrochloride is subjected to setting free of acid in the presence of base and reacted with epichlorohydrin in the presence of a phase transfer catalyst to get...

The present invention relates to an improved process for the preparation of arylthiazole compound of Formula-II by reacting substituted thiobenzamide compound of Formula-III with  β-ketoesters of compound of Formula-IV in a suitable solvent in presence of a base. The present invention further relates to conversion o...

The present invention relates to an improved process for the preparation of Eletriptan hydrobromide both α and β polymorphic forms. The present invention also relates to a process for the preparation of Eletriptan hydrobromide α and β polymorphic forms free of Eletriptan hydrobromide monohydrate. The present inven...

The present invention relates to crystalline salts of Esmirtazapine designated as hydrochloride, fumarate, oxalate, maleate and salicylate. The present invention also relates to process for the preparation of hydrochloride, fumarate, oxalate, maleate and salicylate salts of Esmirtazapine.

The present invention related to process for preparing pure Lumefantrine. The present invention also provides novel impurities of Lumefantrine.

The invention relates to an enzymatic process for preparing ethyl-methyl-carbamic acid-3-[lS-hydroxy-ethyl)-phenyl ester and its further conversion into Rivastigmine.

The present invention provides novel pseudopolymorph of Adefovir dipivoxil, and process for the preparation thereof. The present invention specifically relates to Adefovir dipivoxil formic acid solvate

The present invention provides stable crystalline Form of Pravastatin calcium having moisture content between 6-12% at less than or equal to 50 % relative humidity. The present invention also provides stable crystalline Form of Pitavastatin calcium having moisture content between 6-12% at above 50 % relative humidit...

The present invention provides a process for the preparation of esomeprazole magnesium containing R-isomer in the range of 0.1 to 0.5% by weight. The present invention further relates to a pharmaceutical composition comprising esomeprazole magnesium containing R-isomer in the range of 0.1 to 0.5% by weight. ...

The present invention relates to an improved process for the preparation of Tenofovir by reacting adenine of formula-II, wherein P is H or amino protecting group with Di-alkyl-p-toluenesulfonyloxymethyl phosphonate in presence of metal hydrides with a metal catalyst; or dialkyl Magnesium in a suitable solvent to obt...

The present invention relates to stable amorphous dispersion comprising Vorinostat, a dispersing agent and optionally other pharmaceutically acceptable excipients.

The present invention relates to novel process for the preparation of Asenapine or its pharmaceutically acceptable salts.

Abstract The present invention relates to the novel compounds Methyl 2-[(3S)-[3-[(2E)-(7-chloro quinolin-2-yl) ethenyl] phenyl]-3-halopropyl] benzoates (IV) wherein the halo is chloro, bromo, iodo, starting from the known compound Methyl 2-[(3S)-[3-[(2E)-(7-chloroquinolin-2-yl) ethenyl] phenyl]-3-hydroxypropyl] ben...

The present invention provides a process for the preparation of Lansoprazole comprising the steps of oxidizing 2-[[(3-methy1-4-(2,2,2,-trifluoroethoxy)pyridinyl]methyl]thio]-1H-benzimidazole with an oxidizing agent, washing the reaction mass with aqueous solution of buffer, alkali bicarbonate & alkali thiosulphate, ...

NA

The invention relates to tadalafil compositions comprising tadalafil or its pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable excipient, wherein the composition comprises a solid dispersion of crystalline tadalafil. The invention also relates to process of preparing a solid disper...

A monolithic tablet fonnulation comprising: a) a nucleotide analog reverse transcriptase inhibitor (NtRTI); b) a non-nucleoside reverse transcriptase inhibitors (NNRTI); c) a nucleoside analog reverse transcriptase inhibitors (NRTI) and d) one or more phannaceutically acceptable carriers or excipients. Also di...

The present invention provides a method of quantification of Pentosan Polysulfate sodium characterized by Capillary Electrophoresis. The present also provides a process for the preparation of pure Pentosan.

The present invention provides a novel solvate of sumatriptan succinate, wherein the solvate is an ethanol solvate and is characterized by using different solid state techniques such as powder X-ray diffraction, differential scanning calorimetry and thermo gravimetric analysis. In addition, the present invention dis...

The present invention provides novel crystalline polymorphic forms of desloratadine designated as Form A and Form B, wherein said forms are characterized by different solid state techniques such as powder X-ray diffraction, differential scanning calorimetry, thermo gravimetric analysis and moisture content. Further,...

PROCESS FOR PREPARING (S)-3-(AMINOMETHYL)-5-METHYLHEXANOIC ACID Abstract of the Invention Disclosed herein is a process for the preparing (S)-3-(aminomethyl)-5-methylhexanoic acid by optical resolution of (+)-3-(aminomethyl)-5-methylhexanoic acid and a resolving agent employing a suitable solvent. ...

NA

The present invention relates to a process for the preparation of amorphous valsartan by spray drying.

The present invention relates to novel polymorphic forms of 4-((4-((4-((lE)-2-cyanoethenyl)-2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile [Rilpivirine] designated as Form III, Form IV, Form V and amorphous and processes for the preparation of the same. The present invention also relates to improved proc...

The present invention relates to process for the preparation of amorphous Fexofenadine hydrochloride and further relates to process for the preparation of amorphous Fexofenadine hydrochloride from Fexofenadine DMF solvate.

The invention relates to process for the preparation of Candesartan cilexetil. More particularly, it relates to the preparation of pure candesartan cilexetil by the deprotection of Trityl candesartan cilexetil with inorganic acids.

1) Mannitol co-crystal of Perindopril (L)-Arginine 2) A process for the preparation of mannitol co-crystal of Perindopril (L)-Arginine comprising the steps of: a) dissolving benzyl perindopril in a solvent; b) hydrolyzing benzyl perindopril to perindopril free acid; c) treating the free acid of step b) w...

The present invention relates to a novel and improved process for the preparation of 1-deamino-8-D-arginine vasopressin (Desmopressin) or its pharmaceutically acceptable salts thereof and also relates to improved process for the purification of Desmopressin or its pharmaceutically acceptable salts. Further, the pres...

The present invention relates to pharmaceutical compositions comprising at least one proton pump inhibitor, that is designed such that a core containing proton pump inhibitor is coated with modified semi-permeable membrane, which loses its semi-permeable characteristics during passage in the gastro-intestinal tract ...

The present invention relates to an Industrially advantageous process for the production of lisinopril dihydrate which is selective and does not involve column chromatographic techniques. Also the process is economically advantageous and saves the time consumed in cumbersome extraction methods .Present invention als...

The present invention provides novel crystalline polymorphic forms of Losartan Potassium characterized by powder X-ray diffraction pattern and infrared absorption spectrum along with the novel process for the preparation of crystalline Losartan potassium Form VIII by contacting Losartan potassium with dimethyl forma...

The present invention relates to an improved process for the preparation of 2-[6-methyl-2-(4-methyl-phenyl)-imidazo[1,2-a]pyridin-3-yl]-acetic acid and further conversion of the said compound to tartarate salt of 6-methyl-2-[4-methylphenyl] imidazo [1, 2-a] pyridine-3-N,N-dimethyl acetamide [Zolpidem]. ...

The present invention provides pure Paliperidone comprising less than about 0.1% , preferably less than about 0.05% of PLP keto impurity as well as pur/Ication processes for preparing thereof

The present invention provides an improved process for the preparation of crystalline Atorvastatin calcium Form-I by suspending any crystalline form of Atorvastatin in water or mixture of water and water miscible organic solvent and isolating Atorvastatin Calcium Form I.

Present invention relates to an improved process for the preparation of thiazolidinedione derivatives. Further the invention provides the hydrogenation of acid addition salt of benzylidene compound with less reducing agent under low Hydrogen gas pressure to get substantially pure thiazolidinedione derivatives with i...

The present invention relates to novel crystalline forms of Lopinavir, herein designated as Form-A, Form-B and Form-C. This invention also relates to process for the preparation of Lopinavir polymorphic Form-A, Form-B and Form-C, wherein Lopinavir is dissolved in a organic acids followed by precipitation with additi...

Process for Preparation of 4-[4-(4-(Hydroxydiphenylmethyl-l-Piperidinyl-l-Oxobutyl]-a,a-DimethylbenZene Acetic Acid Methyl Ester and Use Thereof Abstract of the Invention The present invention provides an improved process for preparing fexofenadine, its pharmaceutically acceptable salts and solvates thereof, the ...

The present invention relates to a process for preparation of N-substituted heterocyclic derivative,2-n-Butyl-4-chloro-l-{ [2'-(2-triphenylmethyl-2H-tetrazole-5-yl)-1, 1 '-biphenyl -4-yl] methyl} -lH-imidazole-5-methanol, an important intermediate in the synthesis of Losartan and its pharmaceutically acceptable salt...

The present invention relates to a method for oxidation of sulfide analog with sodium hypochlorite in methylene chloride, and also an improved process for the purification of pantoprazole sodium sesquihydrate.

The present invention relates to process for the preparation of Paroxetine hydrochloride, wherein Paroxetine-N-phenyl carbamate is isolated as a crystalline solid and further subjected to hydrolysis and converted into Paroxetine hydrochloride. According to our present invention N-methyl paroxetine is reacted with ph...

The present invention relates to an improved process for the preparation of Rosiglitazone free base. The present invention also relates to a process for the preparation of Rosiglitazone malonate. The present invention further relates to a process for the preparation of pure Rosiglitazone free base from its malonate ...

The present invention relates to a process for the preparation of Stavudine polymorphic form-I from a mixture containing one or more polymorphic forms by crystallizing in a mixture of solvents.

The invention relates an improved process for preparing the (R)-(-)5-[2-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl]-2-methoxybenzenesulfonamide of Formula I and its pharmaceutically acceptable salts.

The present invention relates to hydrogenation of benzyl perindopril in the presence of a catalyst and solvent at atmospheric pressure to give perindopril free acid, which is further converted to perindopril erbumine. The invention also relates to process for the preparation of substantially pure alpha crystalline f...

The present invention relates to a process for the preparation of pure Rabeprazole sulfoxide using the solvent mixture for the extraction steps and this invention further relates to the process for the preparation of amorphous Rabeprazole sodium using pure rabeprazole base in presence of aqueous NaOH and water misci...

The present invention relates to an improved process for the preparation of (l-methyt-piperidin-4yl)-acetaldehyde, a key intermediate for the synthesis of Naratriptan.

The present invention relates to a process for the preparation of irbesartan form-a by crystallization in water & water miscible solvent having the ratio1:99 to 99:1.

Field of invention The present invention relates to novel heterocyclic compounds that may be useful as phosphodiesterase inhibitors (PDEs) in particular phosphodiesterase type 4 inhibitors represented by general formula (I), their derivatives, their analogs, their tautomeric forms, their stereo isomers, their biois...

ABSTRACT: The present invention relates to stable pharmaceutical compositions for the oral administration of ACE inhibitor(s). It also relates to the novel process of preparing the stable pharmaceutical composition for the oral administration of the ACE inhibitor(s).

The present invention relates to crystalline 3-(S)-(+)-(l-carbamoyl-1,1-diphenylmethyl) pyrrolidine L-(+)-tartrate monohydrate (Darifenacin intermediate) and process for the preparation of Darifenacin intermediate, it is further reacted with 5-(2-bromoethyl) benzo[2,3-b]furan to get Darifenacin which is converted in...

The present invention relates to a novel process for the preparation of Ganciclovir via condensation of guanine with 2-acetoxymethoxy-l,3-acetoxy propane in the presence of a silylating agent, a silylation catalyst and an alkylation catalyst to produce diacetyl ganciclovir, which is isolated in a pure form and furth...

The present invention relates to an improved process for the preparation of Eletriptan hydrobromide by hydrolyzing {R)-1-acetyl-5-(2-phenylsulphonylethenyl)-3-(N- methylpyrrolidin-2-ylmethyl)-1H-indole, followed by reduction in the presence of a metal catalyst, methanesulphonicacid In a solvent, to get the Eletrip...

The present invention provides a process for the preparation of Olmesartan medoxomil comprising the steps of racting trityl Olmesartan medoxomil with an acid in water and immiscible solvent to obtain Olmesartan medoxomil in aqueous solution thereby leaving triphenyl carbinol in the organic layer. The aqueous solutio...

The present invention disclosed 1-(Carbazol-4-Yloxy-3-(2-(0-methoxyphenoxy) ethyl) amino)-2-propanol phosphate sesquihydrate (Carvedilol dihydrogenphosphate sesquihydrate), methods of preparing the sesquithydrate by adding phosphoric acid to a suspension of Carvedilol in water or an organic solvent or a mixture of w...

The present invention relates to a solid oral proton pump inhibitor formulation ii comprising a core which contains: a) a proton pump inhibitor, b) at least one water soluble binder, c) optionally an alkaline agent and/ or a surface active agent, and d) an enteric coating layer applied onto said core, wherei...

The present invention relates to an improved process for the preparation of 3,4-0-anisyliciene-7(S)-chloro-7-deoxy-lincomcin hydrochloride, a key intermediate in the synthesis of Clindamycin Palmitate hydrochloride which in turn is converted to Clindamycin Palmitate hydrochloride by condensation with palmitoyi chlo...

The invention relates to stable amorphous dispersion comprising dexlansoprazole, a dispersing agent(s), and optionally other pharmaceutically acceptable excipient. The invention also relates to processes for preparing stable amorphous dispersion comprising dexlansoprazole, a dispersing agent(s), and optionally other...

A solid pharmaceutical dosage form comprising a solid dispersion of at least one anti retro viral drug and at least one pharmaceutically acceptable water-soluble non-polymeric excipient and at least one pharmaceutically acceptable surface active agent is disclosed.

A solid pharmaceutical dosage form providing improved oral stability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprising a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble carrier and at least one pharmaceutically ac...

The invention provides stable pharmaceutical compositions comprising triptan and processes for preparing them, wherein said compositions are preferably in the form of an orally disintegrating tablet.

The present invention relates to novel polymorphic forms of Raltegravir and processes for its preparation thereof. The present invention further relates to an improved process for preparation of amorphous and crystalline Form 1, Form 2 and Form 3 of Raltegravir potassium salt.

The present invention relates to novel process for the preparation of 4-hydroxy Atomoxetine or its pharmaceutically acceptable salts thereof. The present invention also relates to novel intermediates used in the preparation of 4-hydroxy Atomoxetine.

The present invention provides a method for preparing pure Rizatriptan benzoate having purity more than 99.5% and dimer impurity less than 0.1% comprises, i) Condensation of 1,2,4-Triazole with 4-Nitro benzyl bromide to yield 1-(4-nitrophenyl) methyl-1,2,4triazole ii) Reducing the 1-(4-nitrophenyl) methyl-1,2,4-tria...

The present invention relates to an improved process for the preparation of 10-oxo-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide (Oxcarbazepine) by reacting 10-methoxy-5H-dibenz[b,f]azepine (10-methoxyiminostilbene) and alkali metal cyanate in presence of a-hydroxy acids, and also relates to the process for the ...

The present invention relates to the alkyl amine salts of Montelukast and methods for their preparation and conversion of Montelukast amine salts to Montelukast or Montelukast alkali/alkaline salts.

In particular, Zolmitriptan, which includes a) Preparation of (S)-4-(4-nitrobenzyl)-1,3- oxazolidine-2-one by treating (S)-2-amino-3- (4-nitrophenyl) propanol with triphosgene in presence of potassium carbonate b) Reducing the (S)-4-( 4-nitrobenzyl)-1 ,3-oxazolidin- 2-one under pressure in presence of Raney Nickel ...

The present invention provides an improved process for the preparation of Eprosartan or its pharmaceutically acceptable salt comprising the steps of: condensing compound of formula (a) with compound of formula (b) in presence of a catalyst, in a solvent to get a compound of formula (c), and hydrolyzing the compound ...

The present invention relates to the process for the preparation of Darunavir, solvates or pharmaceutically acceptable salts with improved yield and quality having the difuranyl impurity of formula (1) less than 0.1%. The present invention also relates to provide processes for the preparation of amorphous Darunavir....

Transient receptor potential (TRP) channel proteins constitute a large and diverse family of proteins that are expressed in many tissues and cell types. One TRP channel protein of particular interest is the vanilloid receptor 1 (TRPV1 or VR1), a non-selective channel that is the niolecular target of vanilloid compou...

CRYSTALLINE FORM OF 2-(2-HYDROXY PHENYL)BENZ[E] [l,3]OXAZIN-4- ONE, PROCESS FOR THE SAME AND USE FOR PRODUCING 4-(3,5-BIS(2- HYDROXYPHENYL)-lH-l,2,4-TRIAZOL-l-YL)BENZOICACID Abstract of the Invention The present invention relates to a crystalline form of 2-(2-hydroxyphenyl) benz [e] [1, 3] oxazin-4-one, a proces...

Abstract of the Invention Disclosed herein discloses a crystalline form of 2-Chloro-3-[4-(4-chlorophenyl) cyclohexyl] [l,4]naphthoquinone and process for preparing the same and use thereof. The present invention also provides a process for producing 2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-l,4-naphthoquinone empl...

Provided are novel solvates of Warfarin sodium namely Acetone- ethyl acetate solvate, ethyl acetate solvate, Ethanol-Heptane solvate, Acetone-Heptane solvate and methods for their preparation. Also provided are methods for making Warfarin sodium from Warfarin via the novel solvates.

The present invention provides an improved process for the preparation of Risedronate sodium hemipentahydrate by employing sulfones and water as a solvent system.

Present invention is to provide one pot synthesis of Candesartan without isolating the ester intermediate. Ester intermediate is hydrolyzed in situ with an alkali to get Candesartan.

The present invention relates to a novel process for preparation of 4-(6-oxo-l,6-dihydro pyrimidin-2-yl-amino) benzonitrile, an intermediate of Rilpivirine and further conversion of the said intermediate [4-(6-oxo-l,6-dihydro pyrimidin-2-yl-amino) benzonitrile] to Rilpivirine.

Disclosed herein are novel amine salts of tenofovir and a process for producing the same. In addition, provided is a crystalline form of chloromethyl isopropyl carbonate solvate of tenofovir disoproxil. Furthermore, a process for producing tenofovir disoproxil and its pharmaceutic ally acceptable salt in high purity...

Disclosed herein an enzymatic process for preparing (S)-(-)-10-acetoxy-10,l l-dihydro-5H-dibenz[b,f]azepine-5-carboxamide (eslicarbazepine) and its esters thereof. Further, the invention provides novel intermediates of eslicarbazepine and isomers thereof, enabling high purity and yield of eslicarbazepline. ...

The present invention relates to novel salts of Lamivudine and method for the preparation thereof. The present invention also relates to processes for the preparation of crystalline Lamivudine Form-I and Form-II from novel salts of Lamivudine.

The present invention relates to an oral pharmaceutical composition comprising an intimate admixture of effective amount of ACE inhibitor and a water-soluble polymer. The composition optionally further includes other pharmaceutically acceptable excipients. A process of preparing the composition includes preparing an...

The present invention provides pharmaceutical compostion comprising armodafmil, processes for preparing such pharmaceutical composition. The pharmaceutical compositions of the invention comprises armodafinil, colloidal silicon dioxide and optionally one or more pharmaceutically acceptable excipients. ...

The present invention relates to an improved process for the preparation of stable Lamivudine Form I.

The present invention relates to process for the preparation of amorphous Darunavir.

The invention relates to oral pharmaceutical composition comprising deferasirox or pharmaceutically acceptable salts, polymorphic forms and mixtures thereof, wherein the active ingredient has a mean particle size less than about 100µm and is present in an amount greater than 66% by weight based on total weight of th...

The present invention discloses stable pharmaceutical tablet composition, comprising desmopressin acetate together with atleast one sugar alcohol and pharmaceutically acceptable excipient, carrier, or mixture thereof, wherein the composition is devoid of disaccharide. Also disclosed is a process for making the stabl...

The present invention relates to a process for the preparation of pharmaceutical acceptable salt of valganciclovir from protected valganciclovir prepared by regioselective enzymatic aminoacylation of Ganciclovir.

The present invention relates to an improved process for the preparation of Clopidogrel bisulfate Form I from clopidogrel free base. Whereas Clopidogrel free base is isolated from Clopidogrel acid addition salt.

The present invention relates to an improved process for preparation of pure Eprosartan and its pharmaceutical acceptable salts.

The invention relates to oral pharmaceutical compositions comprising perindopril arginine, wherein said composition comprises stable amorphous solid dispersion of perindopril arginine in combination with pharmaceutically acceptable carriers and optionally other pharmaceutical excipients. The invention also relates t...

This invention, relates to novel polymorphs of triclabendazole. designated as Form I, Form II as anhydrous forms, Form III, Form IV, Form V as solvates and Form VI as an amorphous, and are characterized by X-ray powder diffraction pattern, Infrared absorption spectrum, thermo gravimetric analysis (TGA), differential...

The invention relates to pharmaceutical compositions comprising an immunosuppressant, for parenteral administration. More particularly, the invention relates to pharmaceutical compositions for parenteral administration, which comprises mycophenolate mofetil or its pharmaceutically acceptable salt thereof. ...

The present invention provides an improved process for the preparation of Anti malarial drugs Dihydroartemisinin hemisuccinate and Artemether from Artemisinin. The present invention also provides novel crystalline forms of Artesunate and Artemether.

Ziprasidone ion-exchange complex comprising ziprasidone or its pharmaceutically acceptable salt thereof and an ion-exchange resin ; the ion-exchange resin selected from a group consisting of polymers or co-polymers of styrene, acrylic and methacrylic acids.

The present invention relates to novel acid addition salt of Rosiglitazone [(5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione] namely, Rosiglitazone malonate and process for preparation thereof The present invention further relates to novel polymorphic forms of Rosiglitazone hydrogensulfa...

The present invention relates to novel crystalline polymorphic forms of 2-|4-(4-chlorophenyl)cyclohexyl]-3-hydroxynaphthalenc-1,4-dione (Atovaquone) hereafter designated as Atovaquone polymorphic Form IV, Form V and process for their preparation. The invention also relates to novel processes for the preparation of p...

The present invention relates to 2-[(2-amino-6-oxo-l,6-dihydro-9H-purin -9yl)methoxy]-3-chloropropyl valinate, a novel impurity of Valgancyclovir hydrochloride and process for the preparation thereof.

The invention relates to a process for the manufacture of salts of citalopram in high purity, y the careful selection of solvents and the careful manipulation of the pH value, citalopram salts may be isolated in the absence of 5-chlorocitalopram, 5-bromocitalo-pram, desmethyl-citalopram and 5-carboxyamide citalopram...

The present invention relates to an improved process for the preparation of prostaglandin and prostaglandin analogues, particularly PGF2a derivatives.

The present invention is directed to novel solvates of Zolmitriptan, herein designated as Form I and Form II, processes for the preparation thereof. Furthermore the present invention is directed to processes for the conversion of form I and form II to Zolmitriptan crystalline form A.

A process for the preparation of novel amorphous montelukast sodium by dissolving montelukast free acid in an organic solvent, converting into its alkali salt followed by vacuum drying or spray drying the solution. Alternatively by dissolution of montelukast sodium in organic solvent followed by vacuum drying or spr...

The present invention provides novel polymorphic Forms R and S of bis [(E)-7-[4-(4-Fluorophenyl)-6-isopropyl-2-[methyl (methylsulfonyl) amino] pyrimidin-5-yl] (3R, 5S)-3, 5-dihydroxyhept-6-enoic acid] calcium Salt (Rosuvastatin calcium). The present invention also provides process for the preparation of novel polymo...

The present invention relates to a novel process for stereoselective synthesis of (3R54R)-4-Acetoxy-3-[1,(R)-tert-Butyldimethylsilyloxyethyl] azetidin-2-one (3), which is a key intermediate in the preparation of Penem and Carbapenem type p-lactam antibiotics. According to the present invention the objective compou...

The present invention relates to a novel Darunavir N, N-dimethylformamide solvate and process for preparation of the same.

An enzymatic process for the preparation of Eslicarbazepine acetate comprising the steps of: a) Suspending rec-Licabazepine in solvent, b) adding acylating reagent and an enzyme c) removing the solvent and d) isolating Eslicarbazepine acetate.

The present invention provides novel acid addition salts of Emtricitabine namely 3-Hydroxy2-naphthoicacid, 4-Methyl salicylic acid, 3-Methylsalicylic acid, 2-Methoxy benzoic acid, 3-Methoxy salicylic acid, 4-Methoxy salicylic acid, 4-Fluoro benzoic acid and the like. The present invention further provides conversion...

The present invention relates to extended release compositions comprising dipyridamole or its pharmaceutically acceptable salts in combination with aspirin or its pharmaceutically acceptable salts and other pharmaceutically acceptable excipients and to processes of their preparation.

The invention relates to solid pharmaceutical compositions comprising a combination of sitagliptin, optionally metformin and one or more pharmaceutically acceptable excipients, wherein said composition is devoid of lubricant and also relates to processes for preparing the same.

The present invention relates to novel polymorphic form of Tiaprofenic acid. The present invention further relates to novel process for the preparation of crystalline polymorphic form of Tiaprofenic acid.

The present invention relates to racemization of an undesired optically active 2-hydroxy-3-methoxy-3,3-diphenylpropionic acid, a key intermediate used in the preparation of Ambrisentan. The present invention also relates to a process for the preparation of desired optically active (S)-isomer of 2-hydroxy-3-methoxy-3...

The invention relates to novel heterocyclic compounds having phosphodiesterase type 4 (PDE IV) inhibiting activity and is represented by general formula (I) defined in the specification. The compounds disclosed in the invention are useful in treating allergic and inflammatory diseases and for inhibiting the producti...

NOT AVAILABLE

The present invention relates to novel organic acid addition salts of 4-((4-((4-(1E)-2-Cyanoethenyl)-2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile [Rilpivirine], The salts include Malonate, Succinate, Adipate, Fumarate, Malate, Maleate, Tartarate and Saccharinate. The present invention also relates to p...

An oral solid pharmaceutical composition comprising combination of niacin and HMG-CoA reductase inhibitor with other pharmaceutically acceptable excipients, which is prepared by compression-coating technique.

The present invention relates to amorphous Elvitegravir, amorphous Elvitegravir sodium, crystalline Elvitegravir sodium and processes for the preparation thereof. The present invention also relates to novel processes for the preparation of Elvitegravir polymorphic forms II & III.

ABSTRACT The present invention relates to an improved process for the preparation of 10-oxo-10,ll-dihydro-5H-dibenz[b,fJazepine-5-carboxamide (Oxcarbazepine) by reacting 10-methoxy-5H-dibenz[b,f]azepine (10-methoxyiminostilbene) and alkali metal cyanate in presence of a-hydroxy acids. And further the present invent...

The present invention relates to novel polymorphic Form of esomeprazole sodium Form-P which is prepared by dissolving in a solvent, treating with an anti-solvent and isolation from the reaction mixture followed by purification in acetone solvent to give pure crystalline esomeprazole sodium polymorphic Form-P. The pr...

The present invention relates to an improved process for the preparation of Nevirapine of formula-l, which comprises reacting the compound of formula II with cyclopropyl amine in the presence of a reagent in a solvent to form a compound of formula III, followed by cyclization in the presence of a base in a solvent t...

The invention relates to a controlled release pharmaceutical composition in the form of mini-tablets comprising an effective amount of acetazolamide and one or more pharmaceutically acceptable excipient. The invention also relates to processes for preparing such controlled release pharmaceutical compositions. ...

The present invention relates to a novel process for the preparation of amorphous Dexlansoprazole from Dexiansoprazole solvate. The present invention also relates to novel processes for the preparation of polymorphic forms IV, VI, amorphous, anhydrous and hemihydrate forms of Dexiarisoprazole. ...

The present invention relates to improved process for the preparation of elvitegravir (12), wherein the compound of formula (6) is protected with suitable protecting agents and further reacted with formula (9) in the presence of tetrakis(triphenylphosphine)-palladium (0) catalyst in tetrahydofuran to get correspondi...

ABSTRACT: The present invention relates to stable solid dosage forms of ritonavir and atazanavir/tipranavir and processes for their preparation. In particular, the solid dosage form has improved stability, similar dissolution profile and being bioequivalent to the commercially available formulations of ritonavir an...

The present invention relates to a crystalline oxybutynin base and process for preparing the same. Further, this invention discloses a process for preparing an acid addition salt of oxybutynin employing the crystalline oxybutynin base.

The present invention relates to processes for the preparation of amorphous Elvitegravir, crystalline Elvitegravir Form I, II & III.

The present invention relates to a solid phase peptide synthesis of Enfuvirtide on TentaGel S RAM without isolating any intermediate.

Present invention relates to an improved process for the preparation of Zopiclone and its enantiomerically enriched isomer (Eszopiclone). 6-(5-Chloropyridin-2-yl)-5-hydroxy-7-oxo-5,6-dihydropyrrolo [3,4-b] pyrazine is reacted with 1-chloro-carbonyl-4-methylpiperazine in the presence of alkali earth metal carbonates,...

This invention relates to citalopram, in particular salts of citalopram and a process for the manufacture of said salts in very high purity

Provided is a cost effective and industrially applicable process for the dealkylation of phosphonate esters using mineral acids as dealkylating agents in place of Trialkylsilylhalides.

The present invention relates to an improved process for the preparation of S-(+)-l[3-(dimethyl-amino)propyl]-1 -(p-fluorophenyl)-5-phthalancarbonitrile oxalate.

The invention relates to pharmaceutical formulation in the form of a tablet comprising NSAID and proton pump inhibitor, wherein said tablet is either a bilayer tablet or an inlay tablet and the invention also relates to the process for preparing the same.

Provided is the process for the preparation of Atomoxetine hydrochloride by the condensation of N,N-dimethyl 3-phenyl-3-chloropropyl amine hydrochloride with o-cresol in presence of a phase transfer catalyst followed by demethylation and resolution. Also provided is the preparation of crystalline Atomoxetine hydroch...

The present invention discloses stable, solid oral Efavirenz formulation having comparable in-vitro dissolution and bioequivalence [in-vivo] profile similar to that of Sustiva. Also disclosed is a process for making the same.

The invention discloses a formulation prepared by granulating anti-retro viral drugs and at least one pharmaceutically acceptable additive, using an organic solvent; milling the granules; finally compressing the milled product to form tablets.

The present invention relates to an improved process for preparing 2,1,3-Benzoxadiazole-4-Carboxaldehyde by treating 4-bromomethyl-2,l,3-Benzoxadiazole with hexamethylene tetramine (hexamine) gives quaternary hexamine salt which upon hydrolysis to get 2,1,3-Benzoxadiazole-4- Carboxaldehyde.

An improved process for the preparation of substantially pure valsartan employing suitable reagents such as chelating agent and reaction conditions.

NA

The present invention provides novel crystalline polymorphic forms and amorphous form of Lamivudine characterized by different solid state techniques. The novel processes for their preparation are also disclosed. Further, the present invention is also directed to novel processes for the preparation of crystalline La...

Disclosed herein is a novel crystalline form of 2-[(R)- (diphenylmethyl)sultinyl]acetamide (Armodafinil), designated as Form X and a process for preparation thereof. Further the present invention provides an improved process for the preparation of pure 2-[(R)-(diphenylmethyl) sultinyl] acetamide Form I from Form X...

The invention relates to enteric-coated multiple-unit pharmaceutical composition comprising benzimidazole compound selected from omeprazole or esomeprazole or their pharmaceutically acceptable salts, characterized in that, said enteric coating comprises a mixture of at least one water-soluble plasticizer and at leas...

An oral osmotic dosage form of paliperidone comprising: a)a core comprising:i.a drug layer; ii.optionally a push layer; iii.A seal-coat layer; b)a semi-permeable membrane having an orifice surrounding said core; wherein said dosage form releases paliperidone in a non-ascending rate of release.

The invention relates to oral controlled release dosage form comprising an atypical antipsychotic agent. More particularly, the invention relates to oral controlled release dosage form comprising paliperidone or its pharmaceutically acceptable salts thereof and the process for preparing the same, wherein said dosage...

The present invention discloses an improved process for producing darifenacin, the process comprising decarboxylating (2S,4R)-4-hydroxy-2-pyrrolidine carboxylic acid followed by in situ tosylation to give l-tosyl-3-(R)-(-)-hydroxypyrrolidine, tosylating the l-tosyl-3-(R)-(-)-hydroxypyrrolidine with methyl-p-tolue...

The present invention relates to an improved process for the preparation of Montelukast sodium.

The invention relates to controlled release composition comprising potassium chloride. More particularly, the invention relates to controlled release composition comprising potassium chloride, ethyl cellulose, atleast one amphiphile and optionally other excipient wherein said composition is prepared by wet granulati...

The invention relates to extended-release compositions comprising donepezil or its pharmaceutically acceptable salts and one or more pharmaceutically acceptable excipients and to their process of preparation, wherein said composition is either a matrix type composition or a matrix-in-reservoir type composition. ...

The present invention relates to process for the preparation of novel crystalline Desmethylvenlafaxine succinate polymorphic Forms-A, B. The present invention also relates to novel processes for the preparation of O-Desmethylvenlafaxine succinate polymorphic Forms-I, II, III and amorphous. ...

The present invention relates to novel polymorphic forms of Perindopril arginine designated as polymorphic form y and amorphous form. This invention also related to process for the preparation of Perindopril arginine polymorphic form y and amorphous form

The present invention relates to a novel process for the preparation of Fosamprenavir or its pharmaceutically acceptable salts thereof by using novel intermediates.

The invention relates a Novel crystalline form of Didanosine and pharmaceutical composition thereof, as well as processes for its preparation and manufacture and its pharmaceutically acceptable salts

The present invention relates process for the preparation of 2-(2-amino-l,6-dihydro-6-oxo-purin-9-yl)-methoxy-3-hydroxy-l-propyl-L-valinate (Valganciclovir). Ganciclovir is reacted with halosilane to give a silylated ganciclovir intermediate, which is further reacted with Z-valine NCA to give protected Valganciclovi...

The present invention relates to amorphous Darifenacin hydrobromide and process for the preparation thereof The present invention further relates to novel process for the preparation of crystalline Darifenacin hydrobromide.

ABSTRACT"The present invention stable, solid oral Valsarlan having comparable in-vitro and biocquivalence profile similar to that of DIOVAN'" and which i.s prepared using wet granulalion technique. Also disclosed is a process for making the same.

ABSTRACT The present invention relates to novel solvates of 4-(3, 5-bis (2-hydroxyphenyl)-lH-l, 2, 4-triazol-l-yl) benzoic acid (Deferasirox) hereafter designated Deferasirox Forms C, D, E & F. This invention further relates to the process for the preparation of Deferasirox forms A, C, D, E, F and amorphous form. ...

The invention relates to controlled release compositions comprising metformin or its pharmaceutically acceptable salts in combination with pioglitazone or its pharmaceutically acceptable salts and one or more pharmaceutically acceptable excipient and to their process of preparation. More particularly the invention r...

The present invention relates to novel Perindopril (L)-Lysine salt. The present invention also related to novel amorphous form of Perindopril (L)-Lysine and novel processes for the preparation of amorphous Perindopril (L)-Lysine.

Disclosed herein are novel compounds which are useful as intermediates for producing substituted sulfoxide compounds and a process for producing the same. Further disclosed is a process for producing the substituted sulfoxide compounds used as pharmacologically active agents, employing the novel intermediates of the...

The present invention relates to a novel crystalline Piperaquine free base and a process for preparation thereof. The present invention also relates to crystalline salts of Piperaquine herein after designated as Piperaquine monophosphate, Piperaquine diphosphate, Piperaquine triphosphate, Piperaquine tetraphosphate...

The present invention relates to novel pseudopolymorphs of Prasugrel hydrochloride namely formic acid pseudopolymorph of Prasugrel Hydrochloride, acetic acid pseudopolymorph of Prasugrel Hydrochloride and Nitromethane pseudopolymorph of Prasugrel Hydrochloride and process for the preparation of the same. The present...

The present invention provides novel polymorphic Form-M of Pitavastatin calcium and process for the preparation of same.

Disclosed herein are novel crystalline polymorphic forms Form I, Form II, Form III, Form IV, Form V, Form VI, Form VII, Form VIII, Form IX, Form X and amorphous form of temazepam characterized by X-ray powder diffraction patterns, DSC, TGA and IR. In addition, the invention describes processes for the preparation of...

The present invention relates to the use of sorbitol and or sucrose esters as a sustained release carrier to provide oral sustained release composition. The invention further relates to the process of preparation of such oral sustained release pharmaceutical compositions

The present invention relates to a novel process for the preparation of stable and pure amorphous valganciclovir hydrochloride using a stabilizer.

The present invention relates to novel process for the preparation of tolmetin sodium, by employing easily available starting material and suitable reaction conditions. This invention is further related to novel crystalline forms of tolmetin methyl ester, tolmetin and tolmetin sodium and their process for the prepar...

Disclosed herein an improved process for producing 5-Fluoro-l-(2R, 5S)-[2-(hydroxymethyl)-l,3-oxathiolan-5-yl]cytosine and its pharmaceutical acceptable salts.

Invention Disclosed herein is a novel process for preparing polymorphic Forms of (S)-6-chloro-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1 -benzoxazin-2-one referred as Ml, I, II, β, and ω.

The present invention relates to an improved, process for large scale production of l-[2-(dimethylamino)-l-(4-phenol)ethyl]cyclohexanol (O-desmethylvenlafaxine) or its pharmaceutically acceptable salts with increased yield and minimal impurities.

The present invention provides an improved process for preparation of crystalline Rasagiline base, wherein Rasagiline salt is dissolved in water, pH is adjusted by using a base to precipitate a solid and obtained solid is dissolved in a halogenated solvent, concentrated followed by addition of non-polar solvent to g...

The present invention relates to a process for preparing amorphous Dexlansoprazole, which comprises dissolving crystalline Dexlansoprazole in alcohol solvent, isolating wet crystalline Dexlansoprazole alcoholate, followed by milling and drying.

The present invention relates to regioselective biocatalytic hydrolysis of bis-valine ester of ganciclovir, an intermediate of valgancyclovir to obtain N-BOC valgancyclovir which can be hydrolysed to obtain valgancyclovir free base.

The present invention relates to novel impurities of Pitavastatin calcium i.e. monocalcium bis{(3R, 5S, 6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3,5-dihydroxy-6-heptenoate}.

The invention discloses solid oral pharmaceutical composition comprising a solid dispersion comprising adefovir which is devoid of sugar alcohol. The invention relates to preparation of solid dispersion which is devoid of sugar alcohol comprising adefovir dipivoxil, a dispersive agent(s) and optionally other pharmac...

The present invention relates to extended release pharmaceutical compositions comprising tramadol or its pharmaceutically acceptable salts, at least one matrix former and optionally other pharmaceutically acceptable excipients. The invention also relates to processes for preparing the extended release compositions o...

Crystalline Tenofovir disproxil Crystalline Tenofovir disoproxil according to claim 1, characterized bz DSC as depicted in Fig 2.

The present invention relates to oral pharmaceutical compositions comprising mesalamine or its pharmaceutically acceptable salts, and mixtures thereof. More particularly, the present invention is related to delayed controlled release pharmaceutical composition comprising mesalamine or its pharmaceutically acceptable...

ABSTRACT: The present invention relates to the use of lactose and sugar alcohols to provide oral modified release pharmaceutical compositions comprising erythromycin derivatives. The invention further relates to the process of preparing ■i the same.

The present invention relates to oral controlled or extended release dosage form comprising metformin which is designed to provide extended absorption and availability of metformin in the body. In particular, the present invention is related to oral extended release dosage forms comprising metformin or pharmaceutica...

NOVEL POLYMORPHIC FORMS OF CARVEDILOL DIHYDROGEN PHOSPHATE AND PROCESS FOR PREPARING THE SAME The present invention provides novel crystalline polymorphic forms and amorphous form of carvedilol dihydrogen phosphate characterized by different solid state techniques. The novel processes for their preparation are als...

The present invention is related to delayed release pharmaceutical compositions comprising mesalamine or its pharmaceutically acceptable salts, and mixtures thereof, wherein said compositions comprise a single enteric coating layer coated over the core, wherein said coating minimizes the impact or negative effects o...

The present invention relates to an improved process for the preparation of 3-(2-(dimethylamono) ethyl)-N-methyl-lH-indole-5-methanesulfonamide (sumatriptan) acid addition salt and the base having enhanced yield and purity. Further the present invention also provides a novel crystalline sumatriptan base. ...

Disclosed herein a process for preparing a pure amorphous quinapril hydrochloride and its other pharmaceutically acceptable salts and packing the same. The process comprises of dissolving or suspending crystalline or solvate form of quinapril hydrochloride in a suitable solvent, adding a second solvent solvent, foll...

Disclosed is a solid dosage form comprising: an angiotensin II receptor antagonist drug, a calcium channel blocker drug, a non-polymeric, water-soluble, pharmaceutically acceptable excipients and optionally other pharmaceutically acceptable excipients, such that the drugs are present in an intimately mixed state in ...

The present invention relates to novel crystalline form A of Fosamprenavir calcium and its process thereof.

The present invention relates to a novel process for the preparation of Esomeprazole or its pharmaceutically acceptable salt thereof. The present invention involves novel intermediates in the preparation of Esomeprazole or its salt. The present invention further relates to a pharmaceutical composition comprising Eso...

The present invention relates to a process for the preparation of pure Naftopidii by reacting 2,3-epoxy-l-(l-naphthyloxy)-propane and l-(2-methoxy-phenyl)-piperazine or its acid addition acid salt in biphasic medium. The present invention also relates to a purification of Naftopidii. The present invention fiirther r...

The invention relates to process for preparing round shape gastroretentive tablet comprising a therapeutically effective amount of gabapentin suitable for once daily dosing. More particularly, the invention relates to process of preparing round shape tablets which is capable of enhancing gastric retention time and p...

The present invention relates to an improved process for the preparation of amorphous Tolvaptan.

The present invention relates to novel enzymatic process for the preparation of Miglitol and deoxynorjorimycin hydrochloride, a key intermediate of Miglitol.

"Novel crystalline forms of Tolvaptan and process for the preparation thereof" The present invention relates to novel crystalline forms of Tolvaptan and process for the preparation thereof.

The present invention provides stable crystalline Form-P of Pitavastatin calcium, monocalcium bis{(3R, 5S, 6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3,5-dihydroxy-6-heptenoate}.

The present invention relates to an improved process for the preparation of chiral alcohols compounds by asymmetric alkynylation of ketones. The chiral alcohols are used in the preparation of HIV reverse transcriptase inhibitor such as Efavirenz.

The present invention relates to the isolated substances of benzazepine derivatives and process for their preparation thereof.

The present invention relates to an improved process for the preparation of Pantoprazole magnesium hemipentahydrate, pharmaceutical compositions comprising the same.

The present invention relates to an enzymatic process for the preparation of (S)-monoester of ethyl 3-(4-chlorophenyl) glutarate, an intermediate in the preparation of R-Baclofen.

The present invention provides an enzymatic process for the preparation of (S)-monoester intermediate of pregabalin. The present invention further provides a process for the preparation of pregabalin using the (S)-monoester intermediate prepared by the enzymatic process. The present invention also provides one pot p...

The present invention relates to an amorphous Valgancyclovir hydrochloride having particle size distribution below 100 urn and process for the preparation thereof.

The present invention relates to novel heterocyclic compounds that are useful as phosphodiesterase inhabitors (PDEs) in particular phosphodiesterase type 4 (PDE IV) inhabitors and phosphodiestrase type 10(PDE 10) inhabitors process for their prepartion pharmaceutical compositions containing them and theri use in tr...

An improved process for the preparation of Thalidomide a TNF-alpha inhibitor by the conversion of N-phthaloyl L-glutamine in presence of an active ingredient of inorganic acid salts such as l,l-Carbonyldi(l,2,4-triazole) as a condensing agent.

The present invention relates to an improved process for the preparation of (S)-5-chloro-a-(cyclopropylethynyl)-amino- a-(trifluoromethyl) benzenemethanol of Formula-II by asymmetric alkynylation of ketones by reaction with a chiral ligand, achiral additives selected from carboxylic acids or phenols, with a base, me...

The present invention relates to novel acid addition salt of sibutramine, [1-(4-chlorophenyl)-N,N-dimethyl-(2-methylpropyl)-cyclobutane] Sibutramine Maleate and the processes for their preparation. The present invention further relates to novel polymorphic forms of sibramine Furmarate, which include an anhydrate ...

The present invention relates to novel Polymorphic Form E of Rilpivirine and its process for the preparation.

The present invention relates to a novel process for preparing Tiotropium bromide monohydrate in a single step with enhanced yield.

The invention relates to amorphous dispersion comprising febuxostat, a dispersing agent(s), and optionally other pharmaceutically acceptable excipients and also the pharmaceutical composition comprising amorphous dispersion of febuxostat and processes for preparing the same.

The present invention relates to novel polymorphic forms of Dexlansoprazole designated as Form I, II, III, IV, V and VI. The present invention also relates to novel processes for the preparation of polymorphic forms I, II, III, IV, V, VI, amorphous, crystalline anhydrous and sesquihydrate of Dexlansoprazole. The ...

The present invention relates to an improved process for the preparation of Asenapine maleate with an improved yield and purity without column chromatography.

The present invention relates to a new industrial feasible process for the preparation of Gabapentin Form-IV by reacting 1,1-cyclohexane diacetic acid monoamide with alkali hypo halite followed by acidification with acids in presence of an organic solvent, extracting the liberated acid salt into that solvent...

ABSTRACT:The present invention relates to a novel process for the preparation of Perindopril-(L)-Arginine from protected Perindopril. The invention further relates to process for the purification of Perindopril-(L)-Arginine.

The present invention provides a cost-effective, industrially feasible process for the manufacture of crystalline Carvedilol Form-II using novel Carvedilol salts comprising a step of reacting 4-(2,3-epoxy propoxy) carbazole (II) with 2-(2-methoxy phenoxy) ethyl amine (III) followed by acidification with mine...